


Summary of the cooperation:
2 Joint Calls in Synthetic Biology
15 funded projects
granted funding volume:
24,3 Mio €




ERA-Net: Jan 2012 - Dec 2014

Consortium (partners + observers): 16 funding organisations from 14 countries
self-sustained ERASynBio initiative: since Apr 2015
Consortium (partners + observers): 13 funding organisations from 12 countries

ERASynBio 1st Joint Call 2013:

1 step application procedure
 -> **55 proposals**
 294 partners; 5% from industry


8 proposals selected for funding
 -> **12,9 Mio Euro Funding**
 35 project partners /9 countries



ERASynBio 2nd joint call 2014:

1 step application procedure
 -> **48 proposals**
 234 partners; 4% from industry

7 proposals selected for funding
 -> **11,4 Mio Euro Funding**
 32 project partners /8 countries



Do you have any specific strategy?

more focused on cutting-edge science in the field of synthetic biology than on industrial application
try to include the top countries worldwide (e.g. USA)

Do you use a special agreement or do you need to address IPR issues too?

IPR issues are important, but ERASynBio does not use any special agreements, refers to the DESCA model agreement.

Discovered difficulties:

Maintain an active network without EC contribution (loss of partners / observers)

Cover "additional activities" (e.g. communication -> public perception, training etc.) without EC contribution

Plans for the future (calls, scopes, cooperation changes etc.):

3rd Joint Call planned in collaboration with ERA-IB and ERA-MBT; publication in 11/2015

Convergence with ERA-IB and ERASysAPP in the planned "ERA-NET Cofund on Biotechnologies" (expected start in 2016/17)